3,482 results on '"DiNardo, Courtney"'
Search Results
2. Author Correction: Hypomorphic Brca2 and Rad51c double mutant mice display Fanconi anemia, cancer and polygenic replication stress
3. Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM)
4. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression
5. Outcomes in Patients With Poor-risk Cytogenetics With or Without TP53 Mutations Treated With Venetoclax and Azacitidine
6. Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome
7. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm
8. Prospective performance of the IWG-2023 criteria and IPSS-M in a phase 2 trial of guadecitabine for higher-risk MDS or CMML
9. Outcome of Patients With Relapsed Acute Promyelocytic Leukemia
10. Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials
11. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor
12. Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML
13. Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome
14. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study
15. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
16. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis
17. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1
18. Hypomorphic Brca2 and Rad51c double mutant mice display Fanconi anemia, cancer and polygenic replication stress
19. Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
20. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
21. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax
22. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
23. Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid Leukemia
24. How I treat acute myeloid leukemia with differentiation therapy
25. A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome
26. Early Mortality as a Quality Indicator in Frontline and Salvage Acute Myeloid Leukemia
27. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia
28. Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results
29. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41
30. Hematopoiesis under telomere attrition at the single-cell resolution
31. Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation
32. Approach Toward Germline Predisposition Syndromes in Patients with Hematologic Malignancies
33. Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1
34. Acute myeloid leukaemia
35. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
36. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial
37. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
38. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
39. Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity
40. Effect of Digital Health Coaching on Self-Efficacy and Patient Reported Outcomes in Individuals with Acute Myeloid and Chronic Lymphocytic Leukemia: A Pilot Randomized Controlled Trial
41. TP53 Y220C mutations in patients with myeloid malignancies
42. Detection of PNH clones can aid in the distinction of aplastic anemia vs inherited BM failure syndromes: a single center experience and review of the literature.
43. Mutation patterns and prognostic implications in acute myeloid leukemia with chromosomal 7 deletions.
44. FLAG-IDA + venetoclax in newly diagnosed (ND) or relapsed/refractory (RR) AML.
45. Outcomes of patients with bone marrow fibrosis in de novo and secondary acute myeloid leukemia.
46. A retrospective comparison of abbreviated course “7+7” vs standard hypomethylating agent plus venetoclax doublets in older/unfit patients with newly diagnosed acute myeloid leukemia.
47. Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes
48. Clonal evolution of hematopoietic stem cells after cancer chemotherapy
49. Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease
50. Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.